| Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
|
| Notes: |
Please also refer to the Cancer Drugs Fund list
Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.
Formulary approved "off-label" use is detailed separately. |
|
| Details... |
| 08.01.05 |
Other antineoplastic drugs |
|
|
 |
Use in accordance with local guidelines
|
|
Abemaciclib tabs
|
Formulary
|
Approved as per NICE technology appraisal guidance
|
 NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
|
Alectinib caps
|
Formulary
|
Approved as per NICE Technology Appraisal guidance
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
|
Arsenic trioxide injection
|
Formulary
|
Approved as per NICE Technology Appraisal guidance
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
|
Atezolizumab injection (lung cancer indications)
|
Formulary
|
Approved for use as per NICE technology appraisal guidance below
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
|
Atezolizumab injection (urothelial cancer indications)
|
Formulary
|
 Approved for use as per NICE technology appraisal guidance below
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
|
Avelumab injection
|
Formulary
|
 Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
|
Axicabtagene ciloleucel cells dispersion for infusion
|
Formulary
|
Approved for use as per NICE technology appraisal guidance
A minimum of four doses of tocilizumab are required to be available for use in the event of cytokine release syndrome and emergency equipment must be available prior to infusion.
Refer to SPC for information on management of cytokine release syndrome.
|
NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
|
Axitinib tabs
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
|
Binimetinib tabs
|
Formulary
|
Approved as per NICE technology appraisal guidance
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
|
Bosutinib tabs
|
Formulary
|
Approved as per NICE Technology Appraisal guidance
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
|
Brentuximab injection
|
Formulary
|
Approved as per NICE Technology Appraisal guidance
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
|
Brigatinib tabs
|
Formulary
|
Approves as per NICE technology appraisal guidance
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
|
Carfilzomib injection
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA457: Carfilzomib for previously treated multiple myeloma
|
Ceritinib caps
|
Formulary
|
Approved for use as per NICE Technology Appraisal guidance (see links below):
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
|
Dabrafenib caps
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA 544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
|
Encorafenib caps
|
Formulary
|
Approved as per NICE technology appraisal guidance
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
|
Eribulin injection
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
|
Ibrutinib caps
|
Formulary
|
Approved for use as per NICE technology appraisal guidance below
|
MHRA Aug 17: Ibrutinib (Imbruvica▼): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
|
Idelalisib tabs
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
|
Inotuzumab ozogamicin injection
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
|
Ketoconazole tabs
|
 Restricted
|
Approved off-label indication:
Management of castration refractory prostate cancer
Dose = 200-400mg three times daily
|
|
|
Lutetium (177Lu) oxodotreotide injection
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
|
Midostaurin caps
|
Formulary
|
Approved as per NICE Technology Appraisal guidance
|
NICE TA523: Midostaurin for untreated acute myeloid leukaemia
|
Niraparib caps
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
|
Nivolumab injection (haematological cancer)
|
Formulary
|
Approved for use as per NICE technology appraisal guidance below
|
MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
|
Nivolumab injection (lung and urothelial cancer)
|
Formulary
|
Approved for use as per NICE technology appraisal guidance below
|
MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
|
Nivolumab injection (skin, head and neck and renal cancers)
|
Formulary
|
Approved for use as per NICE technology appraisal guidance below
|
MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
|
Olaparib caps, tabs
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below)
Due to differences in dosing and bioavailability, capsules and tablets should not be substituted on a milligram-to-milligram basis. To avoid medication errors, prescribers should specify formulation and dose on each prescription.
|
NICE TA381: Olaparib for relapsed, platinum-sensitive, BRCA positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
|
Olaratumab injection
|
Formulary
|
Approved for treating advanced soft tissue sarcoma as per NICE TA465
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
|
Palbociclib tabs
|
Formulary
|
Approved for use as per NICE technology appraisal guidance below
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
|
Panitumumab injection
|
Formulary
|
Approved as per restrictions in the NICE guidance
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
|
Panobinostat caps
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
|
Pegaspargase injection
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
|
Pembrolizumab injection (Hodgkin lymphoma)
|
Formulary
|
Approved for use as per NICE Technology appraisals below
|
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
|
Pembrolizumab injection (lung cancer indications)
|
Formulary
|
For non-small-cell lung cancer as per NICE Technology appraisals below
|
MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
|
Pembrolizumab injection (skin cancer indications)
|
Formulary
|
For skin cancer indications as per NICE technology appraisals below
|
MHRA Jul 17: Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection
NICE TA 553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
|
Pembrolizumab injection (urothelial cancer indications)
|
Formulary
|
For urothelial cancer indications as per NICE Technology appraisals below
|
NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
|
Pertuzumab injection
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
|
Ponatinib tabs
|
Formulary
|
Approved for CML and ALL as per NICE TA451
|
MHRA Apr 2017: Ponatinib (Iclusig▼): risk of vascular occlusive events—updated advice on possible dose reduction
MHRA Oct 2018: Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
|
Regorafenib tabs (gastrointestinal stromal tumours)
|
Formulary
|
Approved for use as per NICE technology appraisal guidance below
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
|
Regorafenib tabs (hepatocellular carcinoma)
|
Formulary
|
Approved for use as per NICE technology appraisal guidance below
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
|
Ribociclib tabs
|
Formulary
|
Approved for use as per NICE technology appraisal guidance below
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
|
Ruxolitinib tabs
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
|
Talimogene laherparepvec injection
|
Formulary
|
Approved for use as per NICE TA guidance
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
|
Tisagenlecleucel cells dispersion for infusion
|
Formulary
|
Approved for use as per NICE technology appraisal guidance
A minimum of four doses of tocilizumab are required to be available for use in the event of cytokine release syndrome and emergency equipment must be available prior to infusion.
Refer to SPC for information on management of cytokine release syndrome.
|
NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
NICE TA567:Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
|
Trametinib tabs
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
|
Streptozocin injection
|
 Unlicensed
|
Locally advanced and metastatic neuroendocrine tumours (predominantly pancreas but also small/large bowel and lung)
For named supervising consultants only in accordance with the prescribing protocol and proforma
|
|
|
| 08.01.05 |
Amsacrine |
|
|
Amsacrine injection
|
Formulary
|
|
|
|
| 08.01.05 |
Bevacizumab |
|
|
Bevacizumab injection
|
Formulary
|
Approved off-label indication:
Treatment of neurofibromatosis type 2
For consultant specialists in accordance with a nationally commissioned service protocol
|
|
|
Bevacizumab injection
|
Formulary
|
Approved as per indications in the Cancer Drugs Fund
|
|
|
| 08.01.05 |
Bexarotene |
|
|
Bexarotene caps
|
Formulary
|
Use in accordance with LCNDG guidance
|
|
|
| 08.01.05 |
Bortezomib |
|
|
Bortezomib injection
|
Formulary
|
For relapsed multiple myeloma as per criteria in the Cancer Drugs Fund
|
NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
|
| 08.01.05 |
Cetuximab |
|
|
Cetuximab injection (colorectal cancer)
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below)
|
MHRA Feb 2014: Cetuximab: Importance of establishing wild type RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
|
Cetuximab injection (head and neck cancer)
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below)
|
NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
|
| 08.01.05 |
Crisantaspase |
|
|
Crisantaspase injection
|
Formulary
|
|
|
|
Asparaginase injection
|
Unlicensed
|
Acute lymphoid leukaemia
|
|
|
| 08.01.05 |
Dacarbazine and Temozolomide |
|
|
Dacarbazine injection
|
Formulary
|
|
|
|
Temozolomide caps (licensed use)
|
Formulary
|
Approved as per NICE technology appraisal guidance
|
NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
|
Temozolomide caps (pancreatic neuroendocrine tumours - off-label)
|
Restricted
|
Approved off-label indication:
Unresectable or metastatic pancreatic neuroendocrine tumours (in combination with capecitabine). Follow local protocol for use.
|
|
|
Temozolomide caps (pituitary adenomas - off-label)
|
Restricted
|
Approved off-label indication:
Treatment of pituitary adenomas refractory to surgery and radiotherapy
Initiation restricted to Consultant Endocrinologists who are part of the Trust MDM, in accordance with a treatment protocol at KCH
|
|
|
| 08.01.05 |
Erlotinib |
|
|
Erlotinib tabs
|
Formulary
|
|
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
|
| 08.01.05 |
Hydroxycarbamide |
|
|
Hydroxycarbamide caps, tabs
|
Formulary
|
Cancer indications
 Non-cancer licensed indications
|
|
|
| 08.01.05 |
Imatinab |
|
|
Imatinib tabs (licensed commissioned use)
|
Formulary
|
Approved as per NICE TA guidance (links below)
Also approved for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) (NHSE commissioned)
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
|
Imatinib tabs (Graft vs Host Disease - off-label)
|
Formulary
|
Approved off-label indication:
Treatment of Graft vs Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation as per NHSE policy 16069/P
|
 NHS England Clinical Commissioning Policy 16069/P: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation
|
| 08.01.05 |
Ipilimumab |
|
|
Ipilimumab injection
|
Formulary
|
Approved as per NICE TA Guidance (see links below)
|
MHRA Jan 2019: Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
|
| 08.01.05 |
Mitotane |
|
|
Mitotane tabs
|
Restricted
|
Treatment of patients with:
- Biochemical or radiological evidence of persistent or relapsed adrenocortical carcinoma
- Apparent complete resection of adrenocortical carcinoma for adjuvant therapy
|
|
|
| 08.01.05 |
Pentostatin |
|
|
Pentostatin injection (Graft vs Host Disease - off-label)
|
Formulary
|
Approved off-label indication:
Treatment of Graft vs Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation as per NHSE policy 16069/P
|
NHS England Clinical Commissioning Policy 16069/P: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation
|
Pentostatin injection (licensed use)
|
Formulary
|
|
|
|
| 08.01.05 |
Platinum compounds |
|
|
Carboplatin injection
|
Formulary
|
|
|
|
Cisplatin injection
|
Formulary
|
|
|
|
Oxaliplatin injection
|
Formulary
|
|
NICE CG131: Colorectal cancer: diagnosis and management
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
|
| 08.01.05 |
Procarbazine |
|
|
Procarbazine caps
|
Formulary
|
|
|
|
| 08.01.05 |
Protein kinase inhibitors |
|
|
Afatinib tabs
|
Formulary
|
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
|
Cabozantinib caps (Cometriq - thyroid cancer)
|
Formulary
|
Approved as per NICE Technology Appraisal guidance (see links below):
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer
|
Cabozantinib tablets (Cabometyx - renal carcinoma)
|
Formulary
|
Approved as per NICE Technology Appraisal guidance (see links below):
|
NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
|
Crizotinib caps
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
|
Dasatinib tabs
|
Formulary
|
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Everolimus tabs (breast cancer)
|
Formulary
|
Approved as per NICE TA guidance (see links below)
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
|
Everolimus tabs (neuroendocrine tumours)
|
Formulary
|
Approved for use in neuroendocrine tumours as per NICE TA449
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
|
Everolimus tabs (renal cancer)
|
Formulary
|
Approved as per NICE TA guidance (see links below)
|
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
|
Everolimus tabs (seizures associated with tuberous sclerosis complex)
|
Formulary
|
Approved for use in refractory seizures associated with tuberous sclerosis complex as per NHSE Clinical Commissioning Policy
|
NHSE Clinical Commissioning Policy 170093P: Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex
|
Gefitinib tabs
|
Formulary
|
Approved for use as per NICE technology appraisal guidance (see links below):
|
NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
|
Lenvatinib caps (hepatocellular carcinoma - Lenvima®)
|
Formulary
|
Approved for use as per NICE technology appraisal guidance below
|
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
|
Lenvatinib caps (renal cancer - Kisplyx®)
|
Formulary
|
Approved as per NICE TA guidance (see links below)
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
|
Lenvatinib caps (thyroid cancer - Lenvima®)
|
Formulary
|
Approved for use as per NICE technology appraisal guidance below
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
|
Nilotinib caps
|
Formulary
|
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
|
Nintedanib caps (Vargatef® Non-small-cell lung cancer)
|
Formulary
|
Approved for use in NSCLC as per NICE TA347
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
|
Osimertinib tabs
|
Formulary
|
|
NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
|
Pazopanib tabs
|
Formulary
|
|
NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
|
Sorafenib tablets (Hepatocellular carcinoma)
|
Formulary
|
Approved as per NICE Technology Appraisal guidance
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
|
Sorafenib tablets (thyroid cancer)
|
Formulary
|
Approved as per NICE Technology Appraisal guidance
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
|
Sunitinib caps (neuroendocrine tumours)
|
Formulary
|
Approved for use in neuroendocrine tumours as per NICE TA449
|
MHRA Jan 2011: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
|
Sunitinib caps (renal cell, and gastrointestinal stromal tumours)
|
Formulary
|
Approved for use in renal cell and gastrointestinal stromal tumours as per NICE TA169 and NICE TA179
|
MHRA Jan 2011: Bevacizumab and sunitinib: risk of osteonecrosis of the jaw
NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
|
Tivozanib caps
|
Formulary
|
Approved as per NICE TA guidance (see links below)
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma
|
Vemurafenib tabs
|
Formulary
|
|
NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
|
| 08.01.05 |
Taxanes |
|
|
Cabazitaxel injection
|
Formulary
|
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
|
Docetaxel injection
|
Formulary
|
|
NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer
|
Paclitaxel albumin injection (Abraxane)
|
Formulary
|
Approved as per NICE Technology Appraisal guidance
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
|
Paclitaxel injection
|
Formulary
|
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
|
| 08.01.05 |
Topoisomerase I inhibitors |
|
|
Irinotecan Hydrochloride injection
|
Formulary
|
|
NICE CG131: Colorectal cancer: diagnosis and management
|
Topotecan injection
|
Formulary
|
|
NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
|
| 08.01.05 |
Trabectedin |
|
|
Trabectedin injection
|
Formulary
|
|
NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma
|
| 08.01.05 |
Trastuzumab |
|
|
Trastuzumab emtansine injection
|
Formulary
|
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
|
Trastuzumab injection
|
Formulary
|
Biosimilar products available, to be prescribed by brand name.
Contact pharmacy department for advice on brand for routine prescribing if unsure
|
NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
|
| 08.01.05 |
Tretinoin |
|
|
Tretinoin caps
|
Formulary
|
|
|
|
| .... |
| Non Formulary Items |
Eribulin injection
|
Non Formulary
|
Not approved for use in SE London for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen as per NICE Technology appraisal guidance (see link below) |
NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
|
Necitumumab injection
|
Non Formulary
|
Not approved for use in SE London for untreated advanced or metastatic squamous non-small-cell lung cancer as per NICE Technology appraisal guidance (see link below) |
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
|
Pegylated liposomal irinotecan injection
|
Non Formulary
|
Not approved for use in SE London for treating pancreatic cancer as per NICE Technology appraisal guidance (see link below) |
MHRA Mar 19: Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events
NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
|
Vandetanib tabs
|
Non Formulary
|
Not approved for use in SE London for treating medullary thyroid cancer as per NICE TA550 (see link below) |
NICE TA550: Vandetanib for treating medullary thyroid cancer
|
Vismodegib caps
|
Non Formulary
|
Not approved for use in SE London for treating symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is inappropriate for surgery or radiotherapyas per NICE Technology appraisal guidance (see link below) |
NICE TA489: Vismodegib for treating basal cell carcinoma
|
| |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Specialist or hospital prescribing only.
The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital.
In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.
|
|
Treatment can be initiated in primary care after a recommendation from an appropriate specialist |
|
Specialist initiation followed by maintenance prescribing in primary care |
|
Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation |
|
Specialist and non-specialist initiation |
|
Not recommended for prescribing |
|
|
|
